Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies

Nuclear Medicine Communications

Volumn 32, Issue 4, 2011, Pages 245-251

  Bogsrud, Trond Velde ^a,d   Hay, Ian D ^a   Karantanis, Dimitrios ^a   Nathan, Mark A ^a   Mullan, Brian P ^a   Wiseman, Gregory A ^a   Kasperbauer, Jan L ^a   Reading, Carl C ^a   Björo, Trine ^b,c   Lowe, Val J ^a  

^a MAYO CLINIC   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

18F fluorodeoxyglucose; antithyroglobulin autoantibodies; differentiated thyroid cancer; positron emission tomography; prognosis; thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; THYROGLOBULIN ANTIBODY; THYROTROPIN; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIFFERENTIATED THYROID CARCINOMA; DISEASE COURSE; DRUG UPTAKE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SEROLOGY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROTROPIN BLOOD LEVEL; AGED; COMPUTER ASSISTED EMISSION TOMOGRAPHY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; AGED; AUTOANTIBODIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79952445350     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328343a742     Document Type: Article

References (24)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al.; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid2009; 19:1167-214.
2. Heston TF, Wahl RL. Molecular imaging in thyroid cancer. Cancer Imaging 2010; 10:1-7.
3. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F]-fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85:1107-1113. (Pubitemid 32269357)
4. 18F]-fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin EndocrinolMetab 2006; 91:498-505. [Epub 22 November 2005]. (Pubitemid 43236915)
5. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007; 3:112-121. (Pubitemid 46146964)
6. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. 18F-FDG-PET in the management of patients with anaplastic thyroid carcinoma. Thyroid2008; 18:713-719. (Pubitemid 352009926)
7. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433-1441. (Pubitemid 36623351)
8. Francis Z, Schlumberger M. Serum thyroglobulin determination in thyroid cancer patients. Best Pract Res Clin Endocrinol Metab 2008; 22: 1039-1046.
9. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999; 9:435-441. (Pubitemid 29244919)
10. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008; 46: 1067-1073.
11. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121-1127. (Pubitemid 28496379)
12. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002; 57:215-221. (Pubitemid 34989098)
13. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004; 89: 3702-3704. (Pubitemid 39071459)
14. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005; 90:5566-5575. [Epub 28 June 2005]. (Pubitemid 41415459)
15. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008; 4:223-233. [Epub 12 February 2008]. (Pubitemid 351430907)
16. Görges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005; 153:49-55. (Pubitemid 41030515)
17. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, et al. Disappearance of humoral thyroid autoimmunity aftercomplete removal of thyroid antigens. Ann Intern Med 2003; 139(5 Pt 1):346-351.
18. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47:616-624. (Pubitemid 46768462)
19. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009; 94: 1310-1316. [Epub 21 January 2009].
20. Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY, et al. Value of 18F-FDG-PET-PET/CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 2009; 30:639-650.
21. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hanna L, et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer2009; 115:410-418.
22. Erratum in: Cancer. 2009; 115:1133.
23. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489-499. (Pubitemid 34158210)
24. Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG-PET/CT. Clin Endocrinol (Oxf) 2010; 72:558-563. [Epub 10 September 2009].